Coherus Bio (CHRS) Stock Price, Quote & News

Company Profile

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investi...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 649 3530

Website: www.coherus.com

Address:

333 Twin Dolphin Drive, Suite 600, Redwood City, United States

ralero Apr. 4 at 11:50 PM

$CHRS

0 · Reply

Jack_Nicholson_Truth Apr. 4 at 9:52 PM

$CHRS if you wanna understand more, read what SURF was releasing about chs114 and casdo when they were preclinical into p1/2. Ccr8 was not an accident as Theresa was already trying to develop one in house before chs114. https://www.sec.gov/Archives/edgar/data/1718108/000171810822000006/surf-20211231.htm

1 · Reply

Grandgustav Apr. 3 at 1:12 PM

$CHRS i just got laid off from a job i hated. Denny has my hopes, dreams and quality of life in his hands. But i remain confident that our pipeline is pocket aces

2 · Reply

Toadvind Apr. 3 at 3:24 AM

$CHRS think about this more than I should, almost a year ago now

1 · Reply

Grandgustav Apr. 2 at 1:41 PM

$CHRS

1 · Reply

Jbaffs Apr. 2 at 1:16 PM

$CHRS $OMER 50 days https://www.beckershospitalreview.com/glp-1s/fda-approves-eli-lillys-glp-1-pill-for-weight-loss/

0 · Reply

HansDampf1 Apr. 2 at 11:28 AM

$CHRS In the news: Simply Wall St. Why The Coherus Oncology (CHRS) Story Is Shifting Around Growth Assumptions And Execution Risk https://finance.yahoo.com/sectors/healthcare/articles/why-coherus-oncology-chrs-story-231211393.html

0 · Reply

NormaJean Apr. 1 at 8:50 PM

$CHRS someone just loaded 86,158 shares exactly at 4:00 !!!

2 · Reply

HansDampf1 Apr. 1 at 2:03 PM

$CHRS WARNING! "Today's candlestick analysis revealed a bullish pattern, signaling short sellers to proceed with caution. Market sentiment might be shifting toward a bullish direction. " https://www.americanbulls.com/SignalPage.aspx?lang=en&Ticker=chrs🖤

0 · Reply

Grandgustav Apr. 1 at 1:55 PM

$CHRS Longs like me be like...

0 · Reply

Coherus Oncology, Inc. (CHRS) Q4 2025 Earnings Call Transcript

Mar 9, 2026, 4:15 PM EDT - 26 days ago

Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update

Mar 2, 2026, 9:30 AM EST - 4 weeks ago

Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026

Feb 23, 2026, 9:30 AM EST - 5 weeks ago

Coherus Oncology to Participate in Upcoming Investor Conferences

Feb 17, 2026, 4:11 PM EST - 6 weeks ago

Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock

Feb 12, 2026, 9:18 PM EST - 7 weeks ago

Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock

Jan 13, 2026, 4:16 PM EST - 2 months ago

Coherus Oncology, Inc. (CHRS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 6, 2026, 9:30 AM EST - 3 months ago

Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 9:30 AM EST - 3 months ago

Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)

Dec 23, 2025, 11:06 AM EST - 3 months ago

Coherus Oncology: A Two-Pronged March With Mid-2026 Implications

Dec 8, 2025, 8:30 AM EST - 4 months ago

Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma

Nov 10, 2025, 5:01 PM EST - 5 months ago

Coherus Oncology, Inc. (CHRS) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 7, 2025, 5:56 PM EST - 5 months ago

Coherus Oncology, Inc. (CHRS) Q3 2025 Earnings Call Transcript

Nov 7, 2025, 9:00 AM EST - 5 months ago

Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody

Nov 6, 2025, 4:14 PM EST - 5 months ago

Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 6, 2025, 1:54 PM EST - 5 months ago

Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer

Oct 30, 2025, 8:30 AM EDT - 5 months ago

Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025

Oct 10, 2025, 4:32 AM EDT - 6 months ago

4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals

ALDX ALEC BDTX

Oct 3, 2025, 9:05 AM EDT - 6 months ago

Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Oct 1, 2025, 5:02 PM EDT - 6 months ago

Coherus Oncology, Inc. (CHRS) Presents at UBS Virtual Oncology Day Transcript

Oct 1, 2025, 10:43 AM EDT - 6 months ago

Coherus Oncology: Five Readouts Or More Possible In 2026

Aug 25, 2025, 4:55 PM EDT - 7 months ago

Coherus Oncology: On The Shaping Up

Aug 9, 2025, 11:35 AM EDT - 8 months ago

Coherus Oncology, Inc. (CHRS) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:41 PM EDT - 8 months ago

Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 31, 2025, 4:45 PM EDT - 8 months ago

Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025

May 12, 2025, 10:46 PM EDT - 11 months ago

Coherus BioSciences, Inc. (CHRS) Q1 2025 Earnings Call Transcript

May 12, 2025, 4:15 PM EDT - 11 months ago

Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update

May 5, 2025, 4:01 PM EDT - 11 months ago

Coherus to Report First Quarter 2025 Financial Results on May 12, 2025

May 1, 2025, 5:04 PM EDT - 1 year ago

Coherus to Participate in Upcoming Investor Conferences

Apr 28, 2025, 10:10 AM EDT - 1 year ago

Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025

Apr 17, 2025, 5:53 AM EDT - 1 year ago

Coherus BioSciences: Cleaning The Balance Sheet And Developing New Drugs

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise

Mar 25, 2025, 4:30 PM EDT - 1 year ago

Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Mar 10, 2025, 8:52 PM EDT - 1 year ago

Coherus BioSciences, Inc. (CHRS) Q4 2024 Earnings Call Transcript

Mar 10, 2025, 4:12 PM EDT - 1 year ago

Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update

Mar 3, 2025, 8:30 AM EST - 1 year ago

Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025

Feb 24, 2025, 9:08 AM EST - 1 year ago

Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference

Dec 18, 2024, 8:30 AM EST - 1 year ago

Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

Dec 16, 2024, 6:08 PM EST - 1 year ago

Coherus BioSciences: Shedding Pegfilgrastim To Fuel Ongoing Development

Dec 3, 2024, 9:34 AM EST - 1 year ago

Why Is Coherus BioSciences Stock Trading Higher On Tuesday?

Nov 27, 2024, 4:01 PM EST - 1 year ago

Coherus Management to Participate in the 2024 Citi Global Healthcare Conference

Nov 6, 2024, 11:09 PM EST - 1 year ago

Coherus BioSciences, Inc. (CHRS) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:01 PM EST - 1 year ago

Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Oct 30, 2024, 4:20 PM EDT - 1 year ago

Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024

Aug 13, 2024, 10:01 AM EDT - 1 year ago

Evaluating Coherus BioSciences: Udenyca's Success And Loqtorzi's Prospects

Aug 9, 2024, 6:08 PM EDT - 1 year ago

Coherus BioSciences, Inc. (CHRS) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 9:00 AM EDT - 1 year ago

Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024

Jun 27, 2024, 8:26 AM EDT - 1 year ago

Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction

May 31, 2024, 12:04 PM EDT - 2 years ago

Coherus BioSciences: CHS-114 Comes Into View At ASCO, Drug Launches Underway

May 30, 2024, 9:00 AM EDT - 2 years ago

Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference

ralero Apr. 4 at 11:50 PM

$CHRS

0 · Reply

Jack_Nicholson_Truth Apr. 4 at 9:52 PM

1 · Reply

Grandgustav Apr. 3 at 1:12 PM

$CHRS i just got laid off from a job i hated. Denny has my hopes, dreams and quality of life in his hands. But i remain confident that our pipeline is pocket aces

2 · Reply

Toadvind Apr. 3 at 3:24 AM

$CHRS think about this more than I should, almost a year ago now

1 · Reply

Grandgustav Apr. 2 at 1:41 PM

$CHRS

1 · Reply

Jbaffs Apr. 2 at 1:16 PM

$CHRS $OMER 50 days https://www.beckershospitalreview.com/glp-1s/fda-approves-eli-lillys-glp-1-pill-for-weight-loss/

0 · Reply

HansDampf1 Apr. 2 at 11:28 AM

0 · Reply

NormaJean Apr. 1 at 8:50 PM

$CHRS someone just loaded 86,158 shares exactly at 4:00 !!!

2 · Reply

HansDampf1 Apr. 1 at 2:03 PM

0 · Reply

Grandgustav Apr. 1 at 1:55 PM

$CHRS Longs like me be like...

0 · Reply

Jack_Nicholson_Truth Apr. 1 at 1:44 PM

$CHRS sadly market gapped above $1.69 and our mm fills in all the easy gaps as everyone here can attest to. We got low liquidity for now as DENNY LIKELY HAS SOME DATA on both chs114 for hsncc, gastric and casdo. Data is due mid 2026 and now it's q2 2026 CASDO IS OPEN SO THEY ALREADY KNOW RESULTS TO THIS PT. hence they told us it's similar to atori bev.

2 · Reply

Mariabronn Apr. 1 at 11:19 AM

$CHRS

0 · Reply

whateverhappenedthere Mar. 31 at 1:49 PM

$CHRS XBI ripping, more deals, bio deals heating up

2 · Reply

Grandgustav Mar. 31 at 12:12 PM

$CHRS The question right now is, will our drugs represent a true step-level change for cancer patients? And they will, but until our data readouts, it's going to be extremely difficult to verify that I believe they will.

2 · Reply

HansDampf1 Mar. 31 at 12:07 PM

$CHRS In the news: Coherus Biosciences (CHRS) Is One of the Best Penny Stocks, Here is Why "Muhammad Ali Khalid Tue, March 31, 2026 at 9:19 AM GMT+2 2 min read Coherus Oncology Inc. (NASDAQ:CHRS) is one of the 10 best penny stocks that could triple your money." That's exactly my opinion. 😀 https://finance.yahoo.com/markets/stocks/articles/coherus-biosciences-chrs-one-best-071909631.html

1 · Reply

Grandgustav Mar. 30 at 7:15 PM

$CHRS denny holds my hopes and dreams in his hands because my life is shit and i need his help.

1 · Reply

cdlawton07 Mar. 29 at 1:33 PM

$CHRS Found this comprehensive study on CCR8. https://pmc.ncbi.nlm.nih.gov/articles/PMC10669377/ This image from it shows expression levels across different tumor types. I highlighted in green which tumor types CHRS currently has ongoing studies for. HNSCC looks like it could be the most promising of our currently ongoing studies with how highly expressed CCR8 is and if tagmo does what its suppose to.

0 · Reply

Fomoninja Mar. 27 at 7:47 PM

$CHRS Got a message from Hood today. I guess I'm missing out on loaning my chrs shares. Lol!

1 · Reply

Grandgustav Mar. 27 at 7:30 PM

$CHRS tell our clients to buy the Dow at 40,000. Mr. Valentine has set the price.

0 · Reply

joeger3 Mar. 27 at 4:58 PM

$CHRS The following presents a summary of our active partnerships and collaborations that have contingent regulatory and sales milestones as of December 31, 2025: Junshi Biosciences LOQTORZI Remaining Potential Aggregate Milestone Amount $355.0 million (1) Adimab LLC Casdozokitug $10.5 million Vaccinex, Inc Tagmokitug $13.5 million Memorial Sloan Kettering Cancer Center Tagmokitug $7.2 million (1) $65.0 million relates to regulatory milestones for indications that are not currently the subject of our clinical trials and $290.0 million relates to sale

0 · Reply

neofeudal Mar. 27 at 2:35 PM

$CHRS $ONCO is technically an oncologyy company. They buy a robotics company and go up 80%? Hmmm. Dennis, please don’t.

0 · Reply

Grandgustav Mar. 27 at 1:53 PM

$CHRS bought some more to surpass 45,000 total shares owned. I'm securing my ability to procure commercial BJs in my 50s, thanks to Denny and team.

1 · Reply

Market Cap	90.31M
Revenue (ttm)	266.96M
Net Income (ttm)	28.51M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	10.68%
Debt to Equity Ratio	-0.20

Volume	1,822,400
Avg Vol	1,708,078
Day's Range	N/A - N/A
Shares Out	115.93M
Stochastic %K	30%
Beta	1.01
Analysts	Strong Sell
Price Target	$5.26